Dipyridamole
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Dipyridamole: Sick sinus syndrome 2, autosomal dominant
One-Sentence Summary
Dipyridamole is an antiplatelet and vasodilating drug with two valid single-ingredient licences in Canada. The TxGNN model predicts it may be relevant to sick sinus syndrome 2, autosomal dominant, with a score of 0.9989. There are currently no clinical trials and no publications supporting this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Sick sinus syndrome 2, autosomal dominant |
| TxGNN Prediction Score | 0.9989 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not currently available. Dipyridamole is generally known to raise adenosine levels and to inhibit platelet aggregation, but these properties are not documented in the data compiled for this report.
The predicted condition is a rare inherited disorder of the heart’s sinus node (HCN4-related channelopathy). No mechanistic link has been established. Dipyridamole’s adenosine-enhancing effects could in theory influence sinus node function, but increased adenosine activity may worsen slow heart rhythms. This is therefore a potential safety concern rather than a likely benefit. The high TxGNN score has no clinical or literature support behind it.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02244475 | DIPYRIDAMOLE INJECTION, USP | Not recorded | Not recorded |
| 00637734 | PERSANTINE | Not recorded | Not recorded |
Both are single-ingredient products with valid status.
Safety Considerations
- Drug Interactions: Interaction screening returned 100 records. The ones graded Moderate are dexfenfluramine, sibutramine and fenfluramine. Other listed interactions (for example acetylsalicylic acid, cimetidine, omeprazole, metformin, morphine and simvastatin) have no severity grade recorded.
- Theoretical concern for this prediction: Because dipyridamole potentiates adenosine, it could worsen bradyarrhythmia in people with sinus node dysfunction.
For all other safety information, please refer to the package insert.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has a high model score but no supporting clinical trials or publications, and no plausible mechanism. The adenosine-related effects of the drug raise a safety concern in sinus node disease. Evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data for dipyridamole
- Package insert warnings and contraindications from Health Canada
- Preclinical or genetic-model evidence linking dipyridamole to HCN4-related sinus node dysfunction
- A cardiac safety assessment, particularly for bradyarrhythmia
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.